ANALYSIS: Trump Imposes Tariffs on Medicines and Metals — Protectionism Becomes a Weapon of Mass Economic Destruction

ANALYSIS: Trump Imposes Tariffs on Medicines and Metals — Protectionism Becomes a Weapon of Mass Economic Destruction
Credit: Adobe Stock

Building a pharmaceutical plant takes more than a tweet

A plant for producing active pharmaceutical ingredients requires between five and eight years of construction, certification, and compliance with Food and Drug Administration standards. Five to eight years. Not five to eight weeks. The gap between the president’s rhetoric and industrial reality isn’t a chasm—it’s a canyon.

The United States currently imports more than 80% of its active pharmaceutical ingredients from India and China. This figure is undisputed. It has appeared in Government Accountability Office reports for a decade. Every administration has read it. None has built the plants. Neither has Trump. But Trump, for his part, has decided to tax imports before building alternatives.

The Semiconductor Precedent

We’ve seen this movie before. The CHIPS Act of 2022, signed by Joe Biden, promised to bring semiconductor manufacturing back to the United States. Four years later, TSMC’s factories in Arizona are plagued by delays, cost overruns, and cultural conflicts between Taiwanese engineers and American workers. Mass production? Postponed. Again.

If semiconductors—a sector in which the United States has invested tens of billions—are struggling to relocate, imagining that generic drugs and rare earth metals will spring up on American soil simply through the magic of tariffs is wishful thinking. And yet, that is exactly the gamble this administration is taking.

Share this post

facebook icon twitter icon linkedin icon
Copied!